The global drug and gene delivery devices market size was estimated to be USD 430.25 billion in 2023 and is expected to reach at USD 956.20 billion by 2034 with a CAGR of 7.53% during the forecast period 2024-2034. Rising efforts to develop dosage forms that not only maximize the bioavailability of drugs at the target site but also enhance patient convenience, growing introduction of innovative drug delivery systems, including subdermal implants, which come in various forms such as rings & patches, surge in prevalence of various chronic diseases such as cancer, diabetes, & cardiovascular diseases, increasing technological developments in drug delivery, rising need for injectable medications, growing efforts in research & development activities, surge in diabetic population, increasing popularity of self-injectors, pen-injectors, needle-free injectors, & auto-injectors has empowered patients to self-administer medications at home, reducing the need for medical assistance, and growing demand for gene and drug delivery devices are some of the key factors boosting the market growth.
Growing demand for gene and drug delivery devices is predicted to boost the market growth during the forecast period. A drug and gene delivery device is a medical apparatus designed to facilitate the precise delivery of drugs and genes to their intended site of action, while minimizing contact with non-target cells, organs, and tissues. For instance, in May 2022, Jabil Healthcare has introduced the Qfinity autoinjector platform, which is a straightforward, reusable, and modular solution for subcutaneous (SC) drug self-administration. Notably, it offers a more cost-effective option compared to existing alternatives in the market. This aligns with the increasing focus on sustainable drug delivery within the pharmaceutical industry.
By product, sub-retinal injection cannula was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the growing demand for subretinal injection cannulas, which are recognized as a more efficient & precise method of delivering ocular drugs for cell & gene therapies and surge in launch of novel products. For instance, in March 2022, DORC International is thrilled to announce the launch of EVA NEXUS, which has been developed through close collaboration with surgeons around the world and incorporates cutting-edge technology to deliver superior performance, efficiency, and control in the fields of retina, cataract, and combined surgery. EVA NEXUS introduces several innovations aimed at improving surgical performance and efficiency. These include SmartIOP, which works in tandem with the existing EquiPhaco technology to enhance control during cataract surgery, EVA AVETA, an innovative trocar cannula system, and EVA INICIO, which represents the first approved micro-injection system. Additionally, intravenous catheter is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of chronic diseases has led to an increased utilization of intravenous catheters for various purposes, including the administration of intravenous fluids, blood transfusions, chemotherapy, and other medications.
By commercialized drugs, luxturna (drug delivery devices) was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the surge in approvals for gene therapies, with Luxturna. It is the first gene therapy directly administered in the United States to target a disease caused by mutations in a specific gene. For instance, in August 2023, Sysmex Corporation has revealed that the PrismGuide IRD Panel System has been approved for insurance coverage in Japan. This system is the first gene panel testing system for inherited retinal dystrophy (IRD) in Japan, marking a significant development in genetic testing for this condition. Additionally, Yescarta (Drug Delivery Devices) is predicted to grow at fastest CAGR during the forecast period owing to rising demand for safe & effective drugs is evident, with examples including Yescarta, an advanced therapy medicine categorized as a 'gene therapy product.'
By methods, in situ was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the ease of use, growing approvals of new drugs by regulatory bodies and increasing number of clinical trial procedures. For instance, in August 2022, Pell Bio-Med Technology Co., Ltd. has provided sponsorship for a clinical study aimed at assessing the safety and effectiveness of lentiviral-based gene-edited immune cells that have been manufactured by the company and administered to patients. Additionally, ex vivo is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities and increasing efforts for the development of advanced drug delivery systems.
By vector, viral was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the surge in number of clinical trials involving gene therapies utilize viral vectors for transfection and increased success rate in gene transfer compared to alternative methods. Additionally, non-viral is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of various chronic diseases and surge in partnerships within market players. For instance, in November 2022, IMUNON, Inc. and Acuitas Therapeutics have entered into an agreement to jointly assess the combination of IMUNON's PLACCINE nucleic acid vaccine constructs with Acuitas' proprietary lipid delivery technology.
By route of administration, oral was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023. Pharmaceutical companies are concentrating on minimizing the quantity of Active Pharmaceutical Ingredient (API) per dose while enhancing bioavailability at the target site of action. The effectiveness and safety of biotechnology agents are driving significant investments from biopharmaceutical companies in the research and development of these drugs. These biological drugs are progressively supplanting their conventional counterparts, and many of them are susceptible to degradation when administered orally. Additionally, injectable is predicted to grow at fastest CAGR during the forecast period owing to the ongoing developments in injectable devices that facilitate convenient self-injection by patients and rising launch of new products. For instance, in June 2022, Dual Chamber Bags are a novel medication delivery technology that Gufic Biosciences Ltd. has brought to India, where it is being offered for the first time at reasonable costs.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of key players, growing adoption of advanced methods, rising investment in research & development by government & industry players, increasing focus on the development of gene therapies, growing introduction of novel devices. For instance, in June 2022, Roche has unveiled its Human Papillomavirus (HPV) self-sampling equipment. HPV screening plays a critical role in identifying women who may be at risk of developing cervical cancer, enabling early diagnosis and intervention. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness regarding the novel systems, surge in presence of international industry players, growing burden of chronic diseases such as cancer, diabetes, infectious disease, & cardiovascular disease, rising demand for drug or gene delivery devices, and increasing regulatory approvals. For instance, in February 2022, Takeda has obtained approval from the U.S. Food and Drug Administration (USFDA) for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS). This medication is indicated for the prevention of attacks in patients with hereditary angioedema (HAE) who are 12 years of age and older.
Growing demand for gene and drug delivery devices is predicted to boost the market growth during the forecast period. A drug and gene delivery device is a medical apparatus designed to facilitate the precise delivery of drugs and genes to their intended site of action, while minimizing contact with non-target cells, organs, and tissues. For instance, in May 2022, Jabil Healthcare has introduced the Qfinity autoinjector platform, which is a straightforward, reusable, and modular solution for subcutaneous (SC) drug self-administration. Notably, it offers a more cost-effective option compared to existing alternatives in the market. This aligns with the increasing focus on sustainable drug delivery within the pharmaceutical industry.
By product, sub-retinal injection cannula was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the growing demand for subretinal injection cannulas, which are recognized as a more efficient & precise method of delivering ocular drugs for cell & gene therapies and surge in launch of novel products. For instance, in March 2022, DORC International is thrilled to announce the launch of EVA NEXUS, which has been developed through close collaboration with surgeons around the world and incorporates cutting-edge technology to deliver superior performance, efficiency, and control in the fields of retina, cataract, and combined surgery. EVA NEXUS introduces several innovations aimed at improving surgical performance and efficiency. These include SmartIOP, which works in tandem with the existing EquiPhaco technology to enhance control during cataract surgery, EVA AVETA, an innovative trocar cannula system, and EVA INICIO, which represents the first approved micro-injection system. Additionally, intravenous catheter is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of chronic diseases has led to an increased utilization of intravenous catheters for various purposes, including the administration of intravenous fluids, blood transfusions, chemotherapy, and other medications.
By commercialized drugs, luxturna (drug delivery devices) was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the surge in approvals for gene therapies, with Luxturna. It is the first gene therapy directly administered in the United States to target a disease caused by mutations in a specific gene. For instance, in August 2023, Sysmex Corporation has revealed that the PrismGuide IRD Panel System has been approved for insurance coverage in Japan. This system is the first gene panel testing system for inherited retinal dystrophy (IRD) in Japan, marking a significant development in genetic testing for this condition. Additionally, Yescarta (Drug Delivery Devices) is predicted to grow at fastest CAGR during the forecast period owing to rising demand for safe & effective drugs is evident, with examples including Yescarta, an advanced therapy medicine categorized as a 'gene therapy product.'
By methods, in situ was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the ease of use, growing approvals of new drugs by regulatory bodies and increasing number of clinical trial procedures. For instance, in August 2022, Pell Bio-Med Technology Co., Ltd. has provided sponsorship for a clinical study aimed at assessing the safety and effectiveness of lentiviral-based gene-edited immune cells that have been manufactured by the company and administered to patients. Additionally, ex vivo is predicted to grow at fastest CAGR during the forecast period owing to the growing research & development activities and increasing efforts for the development of advanced drug delivery systems.
By vector, viral was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023 owing to the surge in number of clinical trials involving gene therapies utilize viral vectors for transfection and increased success rate in gene transfer compared to alternative methods. Additionally, non-viral is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of various chronic diseases and surge in partnerships within market players. For instance, in November 2022, IMUNON, Inc. and Acuitas Therapeutics have entered into an agreement to jointly assess the combination of IMUNON's PLACCINE nucleic acid vaccine constructs with Acuitas' proprietary lipid delivery technology.
By route of administration, oral was the highest revenue-grossing segment in the global drug and gene delivery devices market in 2023. Pharmaceutical companies are concentrating on minimizing the quantity of Active Pharmaceutical Ingredient (API) per dose while enhancing bioavailability at the target site of action. The effectiveness and safety of biotechnology agents are driving significant investments from biopharmaceutical companies in the research and development of these drugs. These biological drugs are progressively supplanting their conventional counterparts, and many of them are susceptible to degradation when administered orally. Additionally, injectable is predicted to grow at fastest CAGR during the forecast period owing to the ongoing developments in injectable devices that facilitate convenient self-injection by patients and rising launch of new products. For instance, in June 2022, Dual Chamber Bags are a novel medication delivery technology that Gufic Biosciences Ltd. has brought to India, where it is being offered for the first time at reasonable costs.
North America region is anticipated for the highest revenue share during the forecast period owing to the presence of key players, growing adoption of advanced methods, rising investment in research & development by government & industry players, increasing focus on the development of gene therapies, growing introduction of novel devices. For instance, in June 2022, Roche has unveiled its Human Papillomavirus (HPV) self-sampling equipment. HPV screening plays a critical role in identifying women who may be at risk of developing cervical cancer, enabling early diagnosis and intervention. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing awareness regarding the novel systems, surge in presence of international industry players, growing burden of chronic diseases such as cancer, diabetes, infectious disease, & cardiovascular disease, rising demand for drug or gene delivery devices, and increasing regulatory approvals. For instance, in February 2022, Takeda has obtained approval from the U.S. Food and Drug Administration (USFDA) for TAKHZYRO (lanadelumab-flyo) injection in a single-dose prefilled syringe (PFS). This medication is indicated for the prevention of attacks in patients with hereditary angioedema (HAE) who are 12 years of age and older.
Segmentation: Drug And Gene Delivery Devices Market Report 2023 - 2034
Drug And Gene Delivery Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Intravenous Catheter
- Infusion Bags
- Subretinal Injection Cannula
- Sterile Insulin Syringe
- Extension Tube
- Pre-filled Syringe
Drug And Gene Delivery Devices Market Analysis & Forecast by Commercialized Drugs 2023 - 2034 (Revenue USD Bn)
- Kymriah (Drug Delivery Devices)
- Zolgensma (Drug Delivery Devices)
- Yescarta (Drug Delivery Devices)
- Provenge (Drug Delivery Devices)
- Luxturna (Drug Delivery Devices)
- Strimvelis (Drug Delivery Devices)
Drug And Gene Delivery Devices Market Analysis & Forecast by Methods 2023 - 2034 (Revenue USD Bn)
- Ex vivo
- In situ
Drug And Gene Delivery Devices Market Analysis & Forecast by Vector 2023 - 2034 (Revenue USD Bn)
- Non-viral
- Viral
Drug And Gene Delivery Devices Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Transdermal
- Oral
- Topical
- Injectable
- Nasal
- Ocular
- Inhalation
Drug And Gene Delivery Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Drug And Gene Delivery Devices Market: Product Estimates & Trend Analysis
8. Drug And Gene Delivery Devices Market: Commercialized Drugs Estimates & Trend Analysis
9. Drug And Gene Delivery Devices Market: Methods Estimates & Trend Analysis
10. Drug And Gene Delivery Devices Market: Vector Estimates & Trend Analysis
11. Drug And Gene Delivery Devices Market: Route of Administration Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Drug And Gene Delivery Devices Market
14. Europe Global Drug And Gene Delivery Devices Market
15. Asia Pacific Global Drug And Gene Delivery Devices Market
16. Latin America Global Drug And Gene Delivery Devices Market
17. MEA Global Drug And Gene Delivery Devices Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Dendreon Pharmaceuticals
- Pfizer Inc.
- Becton Dickinson and Company
- Novartis AG
- Bluebird bio Inc.
- Kolon Tissue Gene
- Vericel Corporation
- Renova Therapeutics
- Orchard Therapeutics plc Inc.
- Amgen Inc.
- Kite Pharma Inc.
- Helixmith Co.
- Bausch & Lomb Incorporated Ltd (ViroMed Co. Ltd)
- Spark Therapeutics Inc.
- uniQure N.V.
- Castle Creek Biosciences
- Inc (Fibrocell Technologies Inc.)
- Human Stem Cell Institute
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 430.25 Billion |
| Forecasted Market Value ( USD | $ 956.2 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
